Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Ralph Mangusan, DNP, CRNP, Jomy George, PharmD, Elaine S. Jaffe, MD, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Mark Roth, MD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Vickie Ann Marshall, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137188

Published: 2020

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137637

Published: 2020

Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137709

Published: 2020

Journal Articles

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Jagan R. Muppidi, MD PhD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Lydia L. Chou, CRNP, Sarah Evans, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134115

Published: 2020

Journal Articles

Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142633

Published: 2020

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Kathryn Lurain, MD MPH, Thomas S. Uldrick, MD MS, Priscila H. Goncalves, MD, Ramya Ramaswami, MBBS, MPH, Mark N. Polizzotto, Anaida Widell, Seth M. Steinberg, PhD, Elaine S. Jaffe, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Richard F. Little, MD MPH, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2018-99-112169

Published: 2018

Journal Articles

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Christopher Melani, MD, Mark Roschewski, MD, Stefania Pittaluga, MD PhD, Jeffrey Cohen, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 785.

https://doi.org/10.1182/blood-2018-99-116707

Published: 2018

Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD

Blood (2018) 132 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2018-99-110391

Published: 2018

Journal Articles

Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Michail S. Lionakis, MD ScD, Christopher Melani, MD, John A. Butman, MD PhD, Stefania Pittaluga, MD PhD, A. Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, Richard F. Little, MD MPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2018-99-112184

Published: 2018

Journal Articles

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Nakhle S. Saba, MD, A. Nicole Lucas, RN, Allison Jacob, MS, Erik Yusko, PhD, Seth M. Steinberg, PhD, Elaine S. Jaffe, Adrian Wiestner, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2018) 132 (Supplement 1): 147.

https://doi.org/10.1182/blood-2018-99-112573

Published: 2018

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

Blood (2017) 130 (Supplement 1): 375.

https://doi.org/10.1182/blood.V130.Suppl_1.375.375

Published: 2017

Journal Articles

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

Christopher Melani, MD, Stefania Pittaluga, MD PhD, Lydia Yee, CRNP, Andrea Lucas, RN, Margaret Shovlin, RN, Allison Jacob, MS, Kenneth Chan, PhD, Marissa Vignali, PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2017) 130 (Supplement 1): 2728.

https://doi.org/10.1182/blood.V130.Suppl_1.2728.2728

Published: 2017

Journal Articles

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Christopher Melani, MD, Ranjana H. Advani, MD, Mark Roschewski, MD, Kelsey M. Walters, BS, Clara C. Chen, MD, Lucia Barrato, MD, Mark A. Ahlman, MD, Milos D. Miljkovic, MD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2017) 130 (Supplement 1): 2859.

https://doi.org/10.1182/blood.V130.Suppl_1.2859.2859

Published: 2017

Journal Articles

Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study

Blood (2016) 128 (22): 4145.

https://doi.org/10.1182/blood.V128.22.4145.4145

Published: 2016

Journal Articles

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

Mark Roschewski, MD, Kieron Dunleavy, MD, Sattva S. Neelapu, MD, Stefania Pittaluga, MD PhD, Christopher Joseph Melani, MD, Elaine S. Jaffe, MD, Margaret Shovlin, RN, Beryl Crossley, BS, Katie Kong, BS, Allison Jacob, MD, Larry Kwak, Wyndham H. Wilson, MD PhD

Blood (2016) 128 (22): 2943.

https://doi.org/10.1182/blood.V128.22.2943.2943

Published: 2016

Journal Articles

A Druggable TCF4 and BRD4 Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Michele Ceribelli, PhD, Priscilla N Kelly, Stefania Pittaluga, MD PhD, Craig J Thomas, PhD, Boris Reizis, PhD, Louis M. Staudt, MD PhD

Blood (2016) 128 (22): 1513.

https://doi.org/10.1182/blood.V128.22.1513.1513

Published: 2016

NARROW

Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R 2 ) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers

Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

A Druggable TCF4 and BRD4 Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only